Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1320 | EQ001 Placebo Wiki | 1.00 |
| drug4160 | Use of Doctorgram Mobile Application Wiki | 1.00 |
| drug4163 | Use of Remote Pulse Oximeter Wiki | 1.00 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
This is a randomized controlled trial to evaluate the efficacy and safety of itolizumab in subjects hospitalized with COVID-19.
Description: Proportion of subjects who have recovered at Day 28.
Measure: Proportion of subjects who have recovered at Day 28. Time: Day 28Description: Proportion of subjects deceased or requiring mechanical ventilation at Day 28.
Measure: Proportion of subjects deceased or requiring mechanical ventilation at Day 28. Time: Day 28Description: Proportion of subjects deceased at Day 28.
Measure: Proportion of subjects deceased at Day 28. Time: Day 28Description: Number of participants with treatment-related adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE)
Measure: Incidence of treatment-emergent adverse events (TEAEs). Time: Day 90Description: Time to maximum itolizumab serum concentration, Tmax
Measure: Time to maximum itolizumab serum concentration, Tmax Time: Day 28Description: Maximum itolizumab serum drug concentration, Cmax
Measure: Maximum itolizumab serum drug concentration, Cmax Time: Day 28Description: Total itolizumab exposure across time, AUC (from zero to last)
Measure: Total itolizumab exposure across time, AUC (from zero to last) Time: Day 28Description: Including but not limited to IL-1, IL-6, IL-17, TNF-α.
Measure: Inflammatory biomarkers Time: Day 28Description: sCD6, sALCAM
Measure: Pharmacodynamic markers Time: Day 28Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports